MCID: NRC002
MIFTS: 59

Narcolepsy

Categories: Genetic diseases, Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Narcolepsy

MalaCards integrated aliases for Narcolepsy:

Name: Narcolepsy 12 77 54 26 55 38 56 45 15 74 64
Narcolepsy-Cataplexy Syndrome 54 74
Narcoleptic Syndrome 54 26
Gelineau Syndrome 54 26
Paroxysmal Sleep 12 54
Narcolepsy, Without Cataplexy 12
Gelineau's Syndrome 54

Classifications:



External Ids:

Disease Ontology 12 DOID:8986
KEGG 38 H01293
ICD9CM 36 347.0
MeSH 45 D009290
NCIt 51 C84489
SNOMED-CT 69 60380001
ICD10 34 G47.41 G47.419

Summaries for Narcolepsy

NINDS : 55 Narcolepsy is a chronic neurological disorder caused by the brain's inability to regulate sleep-wake cycles. Many people with narcolepsy also experience uneven and interrupted sleep that can involve waking up frequently during the night.  At various times throughout the day, people with narcolepsy experience overpowering bouts of sleep. If the urge becomes overwhelming, individuals will fall asleep for periods lasting from a few seconds to several minutes. In rare cases, some people may remain asleep for an hour or longer.  In addition to excessive daytime sleepiness (EDS), people with narcolepsy experience some or all of the typical symptoms of cataplexy (the sudden loss of voluntary muscle tone), vivid hallucinations during sleep onset or upon awakening, and brief episodes of total paralysis at the beginning or end of sleep called sleep paralysis).  Because narcolepsy is often misdiagnosed as other conditions, it may take years to get the proper diagnosis. The cause of narcolepsy remains unknown.  It is likely that narcolepsy involves multiple factors interacting to cause neurological dysfunction and sleep disturbances.

MalaCards based summary : Narcolepsy, also known as narcolepsy-cataplexy syndrome, is related to narcolepsy 1 and cerebellar ataxia, deafness, and narcolepsy, autosomal dominant, and has symptoms including hemiplegia, excessive daytime somnolence and snoring. An important gene associated with Narcolepsy is PICSAR (P38 Inhibited Cutaneous Squamous Cell Carcinoma Associated LincRNA), and among its related pathways/superpathways are Th17 cell differentiation and Human T-cell leukemia virus 1 infection. The drugs Modafinil and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and eye.

Disease Ontology : 12 A sleep disorder that involves an excessive urge to sleep at inappropriate times, such as while at work.

Genetics Home Reference : 26 Narcolepsy is a chronic sleep disorder that disrupts the normal sleep-wake cycle. Although this condition can appear at any age, it most often begins in adolescence.

NIH Rare Diseases : 54 Narcolepsy is a chronic brain disorder that involves poor control of sleep-wake cycles. People with narcolepsy have episodes of extreme daytime sleepiness and sudden, irresistible bouts of sleep (called "sleep attacks") that can occur at any time, and may last from seconds or minutes. Other signs and symptoms may include cataplexy (a sudden loss of muscle tone that makes a person go limp or unable to move); vivid dream-like images or hallucinations; and/or total paralysis just before falling asleep or after waking-up. Narcolepsy may have several causes, the most common being low levels of the neurotransmitter hypocretin (for various possible reasons). The disorder is usually sporadic but some cases are familial. There is no cure, but some symptoms can be managed with medicines and lifestyle changes.

PubMed Health : 64 About narcolepsy: Narcolepsy (NAR-ko-lep-se) is a disorder that causes periods of extreme daytime sleepiness. The disorder also may cause muscle weakness.Most people who have narcolepsy have trouble sleeping at night. Some people who have the disorder fall asleep suddenly, even if they're in the middle of talking, eating, or another activity.Narcolepsy also can cause:

Wikipedia : 77 Narcolepsy is a long-term neurological disorder that involves a decreased ability to regulate sleep-wake... more...

Related Diseases for Narcolepsy

Diseases in the Narcolepsy family:

Narcolepsy 1 Narcolepsy 2
Narcolepsy 3 Narcolepsy 4
Narcolepsy 5 Narcolepsy 6
Narcolepsy 7

Diseases related to Narcolepsy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 186)
# Related Disease Score Top Affiliating Genes
1 narcolepsy 1 34.8 HCRT HLA-DQB1 HLA-DRB1 MOG P2RY11
2 cerebellar ataxia, deafness, and narcolepsy, autosomal dominant 34.8 DNMT1 HCRT
3 narcolepsy 2 34.4 HCRT HLA-DQB1 HLA-DRB1 NRCLP2
4 idiopathic hypersomnia 33.5 HCRT HLA-DQB1
5 hypersomnia 33.1 HCRT HLA-DQB1 HLA-DRB1
6 sleep disorder 32.6 HCRT HCRTR1 HCRTR2 LEP MOG
7 sleep apnea 31.4 HCRT LEP TNF
8 multiple sclerosis 31.2 HLA-DQB1 HLA-DRB1 MOG TNF
9 autoimmune disease 30.8 HLA-DQB1 HLA-DRB1 MOG TNF
10 apnea, obstructive sleep 30.8 HCRT LEP TNF
11 neuromyelitis optica 30.7 HCRT HLA-DRB1 MOG
12 recurrent hypersomnia 30.6 HCRT HLA-DQB1
13 diabetes mellitus 30.3 HLA-DQA1 HLA-DQB1 HLA-DRB1 LEP TNF
14 acute disseminated encephalomyelitis 30.3 HCRT HLA-DQA1 HLA-DQB1 HLA-DRB1 MOG
15 narcolepsy 7 12.5
16 narcolepsy 4 12.2
17 narcolepsy 5 12.2
18 narcolepsy 3 12.1
19 narcolepsy 6 12.1
20 disseminated sclerosis with narcolepsy 12.0
21 influenza 10.6
22 limbic encephalitis with lgi1 antibodies 10.6 HLA-DQB1 HLA-DRB1
23 achalasia, familial esophageal 10.6 HLA-DQA1 HLA-DQB1
24 autoimmune disease of peripheral nervous system 10.5 HCRT MOG TNF
25 pediatric multiple sclerosis 10.5 HLA-DQB1 HLA-DRB1 MOG
26 autoimmune polyglandular syndrome type 3 10.5 HLA-DQB1 HLA-DRB1
27 chronic beryllium disease 10.5 HLA-DQB1 HLA-DRB1 TNF
28 microscopic colitis 10.5 HLA-DQB1 HLA-DRB1 TNF
29 endometritis 10.5 HLA-DQA1 HLA-DQB1 TNF
30 glaucomatocyclitic crisis 10.5 HLA-DQB1 HLA-DRB1 TNF
31 geographic tongue 10.5 HLA-DQB1 HLA-DRB1 TNF
32 rohhad 10.5 HCRT HCRTR1 HCRTR2
33 panuveitis 10.5 HLA-DQB1 HLA-DRB1 TNF
34 idiopathic bronchiectasis 10.5 HLA-DQA1 HLA-DQB1 HLA-DRB1
35 metal allergy 10.5 HLA-DQB1 HLA-DRB1
36 sympathetic ophthalmia 10.5 HLA-DQA1 HLA-DRB1 TNF
37 lichen planopilaris 10.5 HLA-DQB1 HLA-DRB1
38 guillain-barre syndrome 10.5 HCRT HLA-DQA1 HLA-DQB1 TNF
39 optic neuritis 10.5 HLA-DRB1 MOG TNF
40 primary progressive multiple sclerosis 10.5 HLA-DRB1 MOG TNF
41 focal epithelial hyperplasia 10.5 HLA-DQA1 HLA-DQB1 HLA-DRB1
42 type ii mixed cryoglobulinemia 10.5 HLA-DQB1 HLA-DRB1
43 rubella 10.5 HLA-DQB1 HLA-DRB1 MOG TNF
44 microscopic polyangiitis 10.5 HLA-DRB1 TNF
45 rheumatic fever 10.5 HLA-DQA1 HLA-DRB1 TNF
46 nervous system disease 10.5 ATXN3 MOG TNF
47 autoimmune disease of central nervous system 10.5 HLA-DRB1 MOG TNF
48 rheumatic heart disease 10.5 HLA-DQA1 HLA-DRB1 TNF
49 toxoplasmosis 10.5 HLA-DQA1 HLA-DQB1 TNF
50 vogt-koyanagi-harada disease 10.5 HLA-DQA1 HLA-DQB1 HLA-DRB1

Comorbidity relations with Narcolepsy via Phenotypic Disease Network (PDN):


Hypertension, Essential Hypothyroidism

Graphical network of the top 20 diseases related to Narcolepsy:



Diseases related to Narcolepsy

Symptoms & Phenotypes for Narcolepsy

UMLS symptoms related to Narcolepsy:


hemiplegia, excessive daytime somnolence, snoring, sleep disturbances, sleeplessness, sluggishness

Drugs & Therapeutics for Narcolepsy

PubMedHealth treatment related to Narcolepsy: 64

Narcolepsy has no cure. However, medicines, lifestyle changes, and other therapies can relieve many of its symptoms. Treatment for narcolepsy is based on the type of symptoms you have and how severe they are.Not all medicines and lifestyle changes work for everyone. It may take weeks to months for you and your doctor to find the best treatment.

Drugs for Narcolepsy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 114)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Modafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 68693-11-8 4236
2
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 62-31-7, 51-61-6 681
3
Sodium oxybate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 502-85-2 5360545
4
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
5
Methylphenidate Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 113-45-1 4158
6
Ribavirin Approved Phase 4 36791-04-5 37542
7
Rasagiline Approved Phase 4 136236-51-6 3052776
8
Pramipexole Approved, Investigational Phase 4 104632-26-0 119570 59868
9 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
10 Central Nervous System Stimulants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
11 Wakefulness-Promoting Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
12 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
13 Analgesics Phase 4,Phase 3,Phase 1,Phase 2
14 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
15 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
16 Dopamine Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
17 Antiparkinson Agents Phase 4,Not Applicable
18 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 Anesthetics, Intravenous Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
20 Adjuvants, Anesthesia Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Anesthetics, General Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
22 Pharmaceutical Solutions Phase 4,Phase 3,Early Phase 1
23 Anticonvulsants Phase 4
24 Excitatory Amino Acids Phase 4
25 Tranquilizing Agents Phase 4,Not Applicable
26 Anti-Anxiety Agents Phase 4,Not Applicable
27 Psychotropic Drugs Phase 4,Phase 2,Not Applicable
28 Antimanic Agents Phase 4
29 Excitatory Amino Acid Antagonists Phase 4
30 Sympathomimetics Phase 4,Phase 2,Phase 1
31 Autonomic Agents Phase 4,Phase 2,Phase 1
32 Protective Agents Phase 4,Phase 1,Phase 2
33 Dopamine Uptake Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
34 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
35 Cardiotonic Agents Phase 4
36 Interferon-alpha Phase 4
37 interferons Phase 4
38 Antioxidants Phase 4
39 Dopamine agonists Phase 4
40 Monoamine Oxidase Inhibitors Phase 4
41 Neuroprotective Agents Phase 4
42
Morphine Approved, Investigational Phase 3 57-27-2 5288826
43
Histamine Approved, Investigational Phase 3,Phase 2 51-45-6 774
44
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 3 65-23-6 1054
45
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
46 Narcotics Phase 3
47 Analgesics, Opioid Phase 3
48
Histamine Phosphate Phase 3,Phase 2 51-74-1 65513
49 Histamine H3 Antagonists Phase 3,Phase 2
50 Vitamins Phase 3

Interventional clinical trials:

(show top 50) (show all 113)
# Name Status NCT ID Phase Drugs
1 Exploratory Clinical Study to Evaluate Sodium Oxybate (Xyrem) on Potential Endocrine Changes Completed NCT00345800 Phase 4 Sodium Oxybate (Xyrem)
2 Effectiveness of Modafinil for Treating Fatigue in Adults With HIV/AIDS Completed NCT00118378 Phase 4 Modafinil;Placebo
3 An Eight Week, Double-Blind Efficacy Study of Armodafinil Augmentation to Alleviate Fibromyalgia Fatigue Completed NCT00678691 Phase 4 armodafinil;placebo
4 Pain Expectations in Subjects With Osteoarthritis Completed NCT02155257 Phase 4 Modafinil;Gabapentin;Placebo
5 "Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies" Completed NCT01023672 Phase 4 Armodafinil
6 SWS And Daytime Functioning in Chronic FatiguE Syndrome (SAFFE) Completed NCT02055898 Phase 4 Sodium Oxybate
7 Xyrem and Brain Dopamine in Narcolepsy Recruiting NCT02637076 Phase 4 Xyrem
8 A Pilot of Methylphenidate in Mild Cognitive Impairment and Dementia Participants. Not yet recruiting NCT03811847 Phase 4 Methylphenidate Extended Release Oral Capsule
9 Modafinil Treatment for Sleep/Wake Disturbances in Older Adults Terminated NCT00626210 Phase 4 modafinil
10 Armodafinil for Patients Starting Hepatitis C Virus Treatment Terminated NCT01470651 Phase 4 Armodafinil;Sugar Pill
11 Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's Disease Terminated NCT01048229 Phase 4 Rasagiline;Pramipexole
12 Palliative Morphine With or Without Concurrent Modafinil Unknown status NCT01766323 Phase 3 Modafinil;Placebo
13 Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy. Completed NCT01638403 Phase 3 BF2.649;Vigil;palcebo
14 Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy Completed NCT00107796 Phase 3 Modafinil
15 "Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy" Completed NCT02348593 Phase 3 JZP-110
16 Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy Completed NCT00066170 Phase 3 Xyrem;Xyrem Placebo;Modafinil at established dose;Modafinil (Placebo)
17 PROVIGIL® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome Completed NCT00107848 Phase 3 Modafinil
18 Trial of Xyrem® (Sodium Oxybate) for the Treatment of Narcolepsy Completed NCT00132873 Phase 3 Xyrem (sodium oxybate) oral solution
19 Long Term Open Label Study in Narcolepsy With BF2.649 (Pitolisant) Completed NCT01399606 Phase 3 BF2.649
20 Safety and Efficacy Study of Armodafinil (CEP-10953) in the Treatment of Excessive Sleepiness Associated With Narcolepsy Completed NCT00078377 Phase 3 Armodafinil;Armodafinil;Placebo
21 Assess the Safety and Effectiveness of PROVIGIL Treatment in Children and Adolescents With Excessive Sleepiness Completed NCT00214968 Phase 3 Modafinil
22 "A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA" Completed NCT02348632 Phase 3 JZP-110
23 Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness Completed NCT00228553 Phase 3 Armodafinil 100 to 250 mg/day
24 Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder Completed NCT00078312 Phase 3 CEP-10953 (Armodafinil)
25 Safety and Efficacy of Xyrem Oral Solution (Sodium Oxybate) Compared With Placebo in Narcoleptic Patients Completed NCT00049803 Phase 3 sodium oxybate
26 Efficacy and Safety Study of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy Completed NCT01067222 Phase 3 BF2.649;Modafinil;Placebo
27 Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome Completed NCT00228566 Phase 3 Armodafinil
28 Efficacy and Safety Study of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolespy Completed NCT01067235 Phase 3 BF2.649;BF2.649 add on Modafinil
29 Patient Narcoleptic Treated With BF2.649 (Pitolisant) in add-on to Sodium Oxybate (HARMONY IV) Completed NCT01789398 Phase 3 BF2.649
30 Pitolisant to Assess Weekly Frequency of Cataplexy Attacks and EDS in Narcoleptic Patients (HARMONY CTP) Completed NCT01800045 Phase 3 Pitolisant;Placebo
31 Methylphenidate to Improve Balance and Walking in MS Completed NCT01896700 Phase 2, Phase 3 Methylphenidate;Placebo
32 Armodafinil (Nuvigil), Postoperative Recovery of OSA (Obstructive Sleep Apnea) and Obese Patients Completed NCT02478580 Phase 3 Nuvigil;Placebo
33 Modafinil in Cancer Related Fatigue Completed NCT01440621 Phase 3 Modafinil;Pyridoxine
34 "Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA" Completed NCT02348606 Phase 3 JZP-110
35 Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy Recruiting NCT02720744 Phase 3 Sodium Oxybate;Placebo
36 A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy Active, not recruiting NCT02221869 Phase 3 Xyrem
37 A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy Active, not recruiting NCT03030599 Phase 3 JZP-258
38 Modafinil to Treat Fatigue in Post-Polio Syndrome Terminated NCT00067496 Phase 3 Modafinil
39 A Safety and Effectiveness Study of a Single Dose of JNJ-17216498 in Patients With Narcolepsy Completed NCT00424931 Phase 2 JNJ-17216498;JNJ-17216498;Modafinil
40 A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy Completed NCT01681121 Phase 2 ADX-N05;Placebo
41 A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy Completed NCT01006122 Phase 2 Placebo;PF-03654746
42 A Study of Safety and Efficacy of BTD-001 in Treatment of Patients With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2 Completed NCT02512588 Phase 2 BTD-001;Placebo
43 A Study of the Safety and Effectiveness of ADX-N05 in the Treatment of Excessive Daytime Sleepiness Completed NCT01485770 Phase 2 ADX-N05;Placebo
44 The Effect of Caffeine on the Narcoleptic Patients Completed NCT02832336 Phase 1, Phase 2 Vivarin;Fiber
45 Clarithromycin for the Treatment of Hypersomnia Completed NCT01146600 Phase 2 Clarithromycin followed by placebo;Placebo then Clarithromycin
46 Flumazenil for the Treatment of Primary Hypersomnia Completed NCT01183312 Phase 1, Phase 2 Flumazenil
47 Methylphenidate and Parkinson's Disease Completed NCT00359723 Phase 2 methylphenidate
48 Sodium Oxybate in Schizophrenia With Insomnia Completed NCT00594256 Phase 2 Sodium Oxybate
49 Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories Completed NCT00247572 Phase 2 NRP104
50 Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse Completed NCT00248092 Phase 1, Phase 2 NRP104

Search NIH Clinical Center for Narcolepsy

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: narcolepsy

Genetic Tests for Narcolepsy

Anatomical Context for Narcolepsy

MalaCards organs/tissues related to Narcolepsy:

42
Brain, Testes, Eye, T Cells, Heart, Cortex, Amygdala

Publications for Narcolepsy

Articles related to Narcolepsy:

(show top 50) (show all 2037)
# Title Authors Year
1
DNMT1-complex disorder caused by a novel mutation associated with an overlapping phenotype of autosomal-dominant cerebellar ataxia, deafness, and narcolepsy (ADCA-DN) and hereditary sensory neuropathy with dementia and hearing loss (HSN1E). ( 30911858 )
2019
2
HPLC analysis of CSF hypocretin-1 in type 1 and 2 narcolepsy. ( 30679597 )
2019
3
A Randomized Study of Solriamfetol for Excessive Sleepiness in Narcolepsy. ( 30694576 )
2019
4
A population-based and case-controlled study of children and adolescents with narcolepsy: Health-related quality of life, adaptive behavior and parental stress. ( 30711365 )
2019
5
Pandemrix-induced narcolepsy is associated with genes related to immunity and neuronal survival. ( 30711515 )
2019
6
Assessing readiness to drive in adolescents with narcolepsy: what are providers doing? ( 30734889 )
2019
7
Finding a needle in the haystack-narcolepsy and obstructive sleep apnea. ( 30778912 )
2019
8
CD8+ T cells from patients with narcolepsy and healthy controls recognize hypocretin neuron-specific antigens. ( 30783092 )
2019
9
The role of home sleep testing for evaluation of patients with excessive daytime sleepiness: focus on obstructive sleep apnea and narcolepsy. ( 30803831 )
2019
10
Narcolepsy - A Rare but under-recognized Problem in Children. ( 30819999 )
2019
11
Medical specialty visits and diagnoses received by Saudi patients prior to a diagnosis of narcolepsy. ( 30820852 )
2019
12
Antidepressants for the treatment of narcolepsy: A prospective study of 148 patients in northern China. ( 30837110 )
2019
13
Fluctuation of primary motor cortex excitability during cataplexy in narcolepsy. ( 30847354 )
2019
14
Knowledge Gaps in the Perioperative Management of Adults With Narcolepsy: A Call for Further Research. ( 30882519 )
2019
15
Cortical activation during sleep predicts dream experience in narcolepsy. ( 30911568 )
2019
16
Factors Influencing Time to Diagnosis in Childhood Narcolepsy Type 1. ( 30913957 )
2019
17
Reduced brain amyloid burden in elderly patients with narcolepsy type 1. ( 30387527 )
2019
18
Longitudinal study of narcolepsy symptoms in first, second, and third-degree relatives of simplex and multiplex narcolepsy families. ( 30496948 )
2019
19
Neurobiological and immunogenetic aspects of narcolepsy: Implications for pharmacotherapy. ( 30503715 )
2019
20
The neurobiological basis of narcolepsy. ( 30546103 )
2019
21
Exploration of cardiac sympathetic adrenergic nerve activity in narcolepsy. ( 30573423 )
2019
22
Exploration of autonomic activity in narcolepsy: The riddle remains unsolved. ( 30611631 )
2019
23
The neuronal network of laughing in young patients with untreated narcolepsy. ( 30635496 )
2019
24
Psychiatric symptoms in patients with post-H1N1 narcolepsy type 1 in Norway. ( 30649483 )
2019
25
Genetics of narcolepsy. ( 30652006 )
2019
26
Prospective memory in narcolepsy type 1 patients. ( 30665593 )
2019
27
The development of hypocretin deficiency in narcolepsy type 1 can be swift and closely linked to symptom onset: clues from a singular case. ( 30668802 )
2019
28
Health-Related Quality of Life in Patients With Narcolepsy: A Review of the Literature. ( 30672873 )
2019
29
Multiple sleep latency test in narcolepsy type 1 and narcolepsy type 2: A 5-year follow-up study. ( 29845680 )
2018
30
An overview of hypocretin based therapy in narcolepsy. ( 29623725 )
2018
31
Off-label Sodium Oxybate in Childhood Narcolepsy: A Comprehensive Report. ( 29942729 )
2018
32
Pseudotumor cerebri syndrome in a patient with narcolepsy type 1. ( 29195824 )
2018
33
Changes in Medical Services and Drug Utilization and Associated Costs After Narcolepsy Diagnosis in the United States. ( 29910845 )
2018
34
Nocturnal REM Sleep Without Atonia Is a Diagnostic Biomarker of Pediatric Narcolepsy. ( 29351827 )
2018
35
Continuous intrathecal orexin delivery inhibits cataplexy in a murine model of narcolepsy. ( 29784823 )
2018
36
Leg Movement Activity during Sleep in School-Age Children and Adolescents: A Detailed Study in Normal Controls and Subjects with Restless Legs Syndrome and Narcolepsy Type 1. ( 29365206 )
2018
37
The MSLT is Repeatable in Narcolepsy Type 1 But Not Narcolepsy Type 2: A Retrospective Patient Study. ( 29198301 )
2018
38
Modafinil Reduces Parasympathetic Activity but Does Not Influence Autonomic Reactivity to Orthostatic Load in Narcolepsy Type 1. ( 29901476 )
2018
39
Prostaglandin D2 Receptor DP1 Antibodies Predict Vaccine-induced and Spontaneous Narcolepsy Type 1: Large-scale Study of Antibody Profiling. ( 29449194 )
2018
40
An Epigenome-wide Association Study of DNA Methylation and An Integrated Genetic and Epigenetic Approach for Narcolepsy. ( 29425374 )
2018
41
Anesthetic Management of Narcolepsy Patients During Surgery: A Systematic Review. ( 29257771 )
2018
42
Impact of acute administration of sodium oxybate on heart rate variability in children with type 1 narcolepsy. ( 29880141 )
2018
43
Functional brown adipose tissue and sympathetic activity after cold exposure in humans with type 1 narcolepsy. ( 29771387 )
2018
44
Cyclic hypersomnolence with symptoms of narcolepsy with cataplexy: An unusual presentation of probable immune-mediated encephalitis. ( 29736425 )
2018
45
Remitting Narcolepsy? Longitudinal Observations in a Hypocretin-deficient Cohort. ( 29868885 )
2018
46
Associations Between Neuropsychological, Neurobehavioral and Emotional Functioning and Either Narcolepsy or Idiopathic Hypersomnia in Children and Adolescents. ( 29609710 )
2018
47
Narcolepsy Associated with Pandemrix Vaccine. ( 29855798 )
2018
48
Narcolepsy and Hypothalamic Region Tumors: Presentation and Evolution. ( 29909138 )
2018
49
Opiates increase the number of hypocretin-producing cells in human and mouse brain and reverse cataplexy in a mouse model of narcolepsy. ( 29950444 )
2018
50
Drugs Used in Narcolepsy and Other Hypersomnias. ( 29759269 )
2018

Variations for Narcolepsy

Copy number variations for Narcolepsy from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 177309 3 55147029 55255377 Insertion HCRTR2 Narcolepsy

Expression for Narcolepsy

Search GEO for disease gene expression data for Narcolepsy.

Pathways for Narcolepsy

GO Terms for Narcolepsy

Cellular components related to Narcolepsy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 trans-Golgi network membrane GO:0032588 9.58 HLA-DQA1 HLA-DQB1 HLA-DRB1
2 endocytic vesicle membrane GO:0030666 9.54 HLA-DQA1 HLA-DQB1 HLA-DRB1
3 ER to Golgi transport vesicle membrane GO:0012507 9.5 HLA-DQA1 HLA-DQB1 HLA-DRB1
4 transport vesicle membrane GO:0030658 9.43 HLA-DQA1 HLA-DQB1 HLA-DRB1
5 clathrin-coated endocytic vesicle membrane GO:0030669 9.33 HLA-DQA1 HLA-DQB1 HLA-DRB1
6 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.13 HLA-DQA1 HLA-DQB1 HLA-DRB1
7 MHC class II protein complex GO:0042613 8.8 HLA-DQA1 HLA-DQB1 HLA-DRB1

Biological processes related to Narcolepsy according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.78 ATXN3 HCRT HCRTR1 HCRTR2
2 neuropeptide signaling pathway GO:0007218 9.7 HCRT HCRTR1 HCRTR2
3 antigen processing and presentation of exogenous peptide antigen via MHC class II GO:0019886 9.67 HLA-DQA1 HLA-DQB1 HLA-DRB1
4 interferon-gamma-mediated signaling pathway GO:0060333 9.61 HLA-DQA1 HLA-DQB1 HLA-DRB1
5 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.58 HCRT HCRTR2 P2RY11
6 T cell receptor signaling pathway GO:0050852 9.56 HLA-DQA1 HLA-DQB1 HLA-DRB1 MOG
7 leukocyte tethering or rolling GO:0050901 9.54 LEP TNF
8 negative regulation of glucose import GO:0046325 9.51 LEP TNF
9 antigen processing and presentation GO:0019882 9.5 HLA-DQA1 HLA-DQB1 HLA-DRB1
10 negative regulation of lipid storage GO:0010888 9.46 LEP TNF
11 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.37 HLA-DQB1 HLA-DRB1
12 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.16 HLA-DQB1 HLA-DRB1
13 feeding behavior GO:0007631 9.13 HCRT HCRTR1 HCRTR2
14 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 8.8 HLA-DQA1 HLA-DQB1 HLA-DRB1

Molecular functions related to Narcolepsy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 9.33 HLA-DQA1 HLA-DQB1 HLA-DRB1
2 orexin receptor activity GO:0016499 8.96 HCRTR1 HCRTR2
3 MHC class II receptor activity GO:0032395 8.8 HLA-DQA1 HLA-DQB1 HLA-DRB1

Sources for Narcolepsy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....